Lymphotoxin-alpha/beta heteromeric complex and/or at least one lymphotoxin-beta-R activating agent composition, pharmaceutical preparation, lymphotoxin-beta-R activating agent and the method of its selection

摘要

The invention relates to a pharmaceutical composition comprising at least one LT-beta-R activating agent, wherein one LT-beta-R agent comprises an anti-LT-beta-R antibody, and its use for treating or reducing the advancement, severity or effects of neoplasia. Thereinafter the invention relates to use of an LT-alpha/beta heteromecic complex for the preparation of a pharmaceutical composition designed to be administered in the presence of at least one LT-beta-R activating agent for the treatment or reduction of the advancement, severity or effects of neoplasia. A method for selecting an anti-LT-beta-R activating agent is described.